AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells

Oncotarget

Volumn 5, Issue 16, 2014, Pages 6801-6815

  Maenhout, Sarah K ^a   Du Four, Stephanie ^a,b   Corthals, Jurgen ^a   Neyns, Bart ^a,b   Thielemans, Kris ^a   Aerts, Joeri L ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Immunosuppression; JAK1 2 inhibitors; Myeloid derived suppressor cells; Signal transducer and activator of transcription 3; Tumor immunology

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; AXITINIB; CD45 ANTIGEN; GAMMA INTERFERON; JANUS KINASE 1; JANUS KINASE 2; RUXOLITINIB; STAT3 PROTEIN; SUNITINIB; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL VIABILITY; CELLULAR IMMUNITY; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GRANULOCYTIC MYELOID DERIVED SUPPRESSOR CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MELANOMA; MOLECULAR DYNAMICS; MONOCYTIC MYELOID DERIVED SUPPRESSOR CELL; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN EXPRESSION; SPLEEN CELL; SUPPRESSOR CELL; SURVIVAL TIME; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; C57BL MOUSE; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; PATHOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; JANUS KINASE 2; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MYELOID CELLS; PYRAZOLES; PYRIMIDINES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907068048     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2254     Document Type: Article

References (54)

1. Leibovici J, Itzhaki O, Huszar M, Sinai J. Targeting the tumor microenvironment by immunotherapy: part1. Immunotherapy. 2011;3:1367-84.
2. Leibovici J, Itzhaki O, Huszar M, Sinai J. Targeting the tumor microenvironment by immunotherapy: part 2. Immunotherapy. 2011;3:1385-408.
3. Sawyer TK, Wu JC, Sawyer JR, English JM. Protein kinase inhibitors: breakthrough medicines and the next generation. Expert Opin. Investig. Drugs. 2013;22:675-8.
4. Cohen P, Alessi DR. Kinase drug discovery-what's next in the field? ACS Chem. Biol. 2013;8:96-104.
5. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-45.
6. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res. 2009;15:425-30.
7. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity:a leading role for STAT3. Nat Rev Cancer. 2009;9:798-809.
8. Fagard R, Metelev V, Souissi I, Baran-Marszak F. STAT3 inhibitors for cancer therapy: Have all roads been explored? JAK-STAT. 2AD;1:1-9.
9. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 2007;251:199-210.
10. Johnston PA, Grandis JR. Stat3 signaling: Anticancer Strategies and Challenges. Mol. Interv. 2011;11:18-26.
11. Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, Nishio H, Kawamura N, Kawakami Y. The mechanisms of cancer immunoescape and development of overcoming strategies. Int. J. Hematol. 2011;93:294-300.
12. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005;65:9525-35.
13. Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R, Jove R, Gabrilovich D. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 2004;172:464-74.
14. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel A, Multhoff G, Hamman A, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 2010;120:457-71.
15. Egwuagu CE. STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine. 2010;47:149-56.
16. Lin A, Schildknecht A, Nguyen LT, Ohashi PS. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol. Lett. 2010;127:77-84.
17. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. Elsevier Ltd; 2012;38:904-10.
18. Ball S, Li C, Li P-K, Lin J. The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS One. 2011;6:e18820.
19. Dave B, Landis MD, Tweardy DJ, Chang JC, Dobrolecki LE, Wu MF, Zhang X, Westbrook TF, Hilsenbeck SG, Liu D, Lewis MT. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012;7:e30207.
20. Bournazou E, Bromberg J. Targeting the tumor microenvironment: JAK-STAT3 signaling. Jak-Stat. 2013;2:e23828.
21. Greten FR, Karin M. Peering into the aftermath: JAKi rips STAT3 in cancer. Nat. Med. 2010;16:1085-7.
22. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, et al. The JAK2 inhibitor, AZD1480, potently blocks STAT3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009;16:487-97.
23. Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, Zhang C, Liang W, Scuto A, Weng S, Morosini D, Cao ZA, Zinda M, et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 2011;71:6601-10.
24. Scuto A, Krejci P, Popplewell L, Wu J, Wang Y, Kujawski M, Kowolik C, Xin H, Chen L, Wang Y, Kretzner L, Yu H, Wilcox WR, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia. 2011;25:538-50.
25. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474-88.
26. Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin. Immunol. Elsevier Inc.; 2012;144:250-68.
27. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol. Immunother. 2012;61:255-63.
28. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010;70:4335-45.
29. Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark. Res. 2013;1:5.
30. Yamaoka K, Saharinen P, Pesu M, Holt VET, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol. 2004;5:253.
31. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol. Rev. 2009;228:273-87.
32. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KC, Yin L, Pennica D, Johnson EM jr, Schreiber RD. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998;93:373-83.
33. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 1993;74:227-36.
34. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 2005;280:22788-92.
35. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. Mutational analysis of the tyrosine kinome in colorectal cancers. Science. 2003;300:949.
36. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153-8.
37. Blagosklonny MV. Rapalogs in cancer prevention: anti-aging or anticancer? Cancer Biol. Ther. 2012;13:1349-54.
38. Blagosklonny MV. Immunosuppressants in cancer prevention and therapy. Oncoimmunology. 2013;2:e26961.
39. Athar M, Kopelovich L. Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention. Cancer Prev Res. 2011;4:957-61.
40. Donehower LA. Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency. Aging (Albany. NY). 2012;4:660-1.
41. Livi CB, Hardman RL, Christy BA, Dodds SG, Jones D, Williams C, Strong R, Bokov A, Javors MA, Ikeno Y, Hubbard G, Hasty P, Sharp ZD. Rapamycin extends life span of Rb1+/-mice by inhibiting neuroendocrine tumors. Aging (Albany. NY). 2013;5:100-10.
42. De Groot J, Liang J, Kong L, Wei J, Piao Y, Fuller G. Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in Glioblastoma ABSTRACT: 2012;3:1036-48.
43. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit. Rev. Oncol. Hematol. 2005;56:47-60.
44. Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122:1192-202.
45. Fridman JS, Scherle PA, Collins R, Burn T, Neilan CL, Hertel D, Contel N, Haley P, Thomas B, Shi J, Collier P, Rodgers JD, Shepard S, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J. Invest. Dermatol. Nature Publishing Group; 2011;131:1838-44.
46. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 2012;367:495-507.
47. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, Wainschenk T, Singh-Jasuja H, Brossart P. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood. 2008;111:5610-20.
48. Maenhout SK, Van Lint S, Emeagi PU, Thielemans K, Aerts JL. Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts. Int. J. Cancer. 2014;1:1077-90.
49. Vasquez-dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, Blosser RL, Tam AJ, Bruno T, Zhang H, Pardol D, Kim Y. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J. Clin. Invest. 2013;123:1580-9.
50. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA. Direct and differential suppression of myeloid-derived suppressor cell subsets by Sunitinib is compartmentally constrained. Cancer Res. 2012;70:3526-36.
51. Liu Y, Holdbrooks AT, De Sarno P, Rowse AL, Yanagisawa LL, McFarland BC, Harrington LE, Raman C, Sabbaj S, Benveniste EN, Qin H. Therapeutic Efficacy of Suppressing the JAK/STAT Pathway in Multiple Models of Experimental Autoimmune Encephalomyelitis. J. Immunol. 2013;
52. Miller CP, Thorpe JD, Kortum AN, Coy CM, Cheng WY, Ou Yang TH, Anastassiou D, Beatty JD, Urban ND, Blau CA. JAK2 Expression Is Associated with Tumor-Infiltrating Lymphocytes and Improved Breast Cancer Outcomes: Implications for Evaluating JAK2 Inhibitors. Cancer Immunol. Res. 2014;2:301-6.
53. Su Q, Ioannidis S, Chuaqui C, Almeida L, Alimzhanov M, Bebernitz G, Bell K, Block M, Howard T, Huang S, Huszar D, Read JA, Rivard Costa C, et al. Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J. Med. Chem. 2014;57:144-58.
54. Berger TG, Strasser E, Smith R, Carste C, Schuler-Thurner B, Kaempgen E, Schuler G. Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells. J. Immunol. Methods. 2005;298:61-72.